Literature DB >> 29908284

Downregulation of SCARA5 may contribute to breast cancer via promoter hypermethylation.

Damla Ulker1, Yeliz Emine Ersoy2, Zuhal Gucin3, Mahmut Muslumanoglu4, Nur Buyru5.   

Abstract

Breast cancer is the most common malignant tumor in women worldwide. Breast tumors mostly exhibit aberrant gene expression and DNA hypermethylation patterns that predispose the disease. Understanding the genetic and epigenetic factors that contribute to breast cancer development is important to identify novel diagnostic and prognostic markers. SCARA5: Scavenger receptor class A, member 5; is a member of the scavenger receptor family located on chromosome 8p21 which is a frequently deleted region in human cancers. SCARA5 has been identified as a candidate tumor suppressor gene in various kinds of cancer. However, its role in breast cancer remains unclear. Therefore, in the present study SCARA5 expression levels in breast tumors and matched noncancerous tissue samples from 77 patients were analyzed by qRT-PCR and the expression levels were correlated with the methylation level of SCARA5 gene promoter. We found that SCARA5 expression was significantly decreased in tumors (92.2%) compared to non-cancerous tissue samples and this down-regulation was associated with hypermethylation of the promoter (p < 0.001). A significant correlation was also detected between SCARA5 expression and the histological grade of the breast tumors (p = 0.017). Taken together, our results indicate that SCARA5 may play an important role in tumorigenesis of breast cancer via promoter methylation.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Expression; Promoter methylation; SCARA5

Mesh:

Substances:

Year:  2018        PMID: 29908284     DOI: 10.1016/j.gene.2018.06.036

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  Differential expression of EphA5 protein in gastric carcinoma and its clinical significance.

Authors:  Wei Zhang; Xue Wei; Shuwei Guo; Jiandong Wang; Jing Liu; Hai Wang
Journal:  Oncol Lett       Date:  2019-03-19       Impact factor: 2.967

2.  Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma.

Authors:  Kawuli Jumai; Tangjuan Zhang; Bingzhang Qiao; Julaiti Ainiwaer; Haiping Zhang; Zhichao Hou; Idris Awut; Madinyat Niyaz; Liwei Zhang; Ilyar Sheyhidin
Journal:  J Immunol Res       Date:  2022-06-17       Impact factor: 4.493

3.  Carcinoma-associated fibroblasts release microRNA-331-3p containing extracellular vesicles to exacerbate the development of pancreatic cancer via the SCARA5-FAK axis.

Authors:  Yadong Han; Xu Qian; Teng Xu; Yang Shi
Journal:  Cancer Biol Ther       Date:  2022-12-31       Impact factor: 4.875

4.  Scavenger receptor class A, member 5 is associated with thyroid cancer cell lines progression via epithelial-mesenchymal transition.

Authors:  Chen Zheng; Er-Jie Xia; Rui-Da Quan; Adheesh Bhandari; Ou-Chen Wang; Ru-Tian Hao
Journal:  Cell Biochem Funct       Date:  2020-01-27       Impact factor: 3.685

5.  GWAS-Based Identification of New Loci for Milk Yield, Fat, and Protein in Holstein Cattle.

Authors:  Liyuan Liu; Jinghang Zhou; Chunpeng James Chen; Juan Zhang; Wan Wen; Jia Tian; Zhiwu Zhang; Yaling Gu
Journal:  Animals (Basel)       Date:  2020-11-05       Impact factor: 2.752

Review 6.  Iron: An Essential Element of Cancer Metabolism.

Authors:  Myriam Y Hsu; Erica Mina; Antonella Roetto; Paolo E Porporato
Journal:  Cells       Date:  2020-12-03       Impact factor: 6.600

7.  Tumor suppressive effect of scavenger receptor class A member 5 overexpression in colorectal cancer by regulating PI3K/AKT/mTOR pathway.

Authors:  Yi Li; Feng Peng; Xiangyun Tan; Jin Wang; Yeqing Xu
Journal:  Genes Genomics       Date:  2021-08-21       Impact factor: 1.839

8.  The Novel Methylation Biomarker SCARA5 Sensitizes Cancer Cells to DNA Damage Chemotherapy Drugs in NSCLC.

Authors:  Qi Peng; Yan Liu; Xuehua Kong; Jie Xian; Lin Ye; Li Yang; Shuliang Guo; Yan Zhang; Lan Zhou; Tingxiu Xiang
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.